Selective use of sorafenib in the treatment of thyroid cancer - Wikidata - wikimedia - TriplyDB

Selective use of sorafenib in the treatment of thyroid cancer

Selective use of sorafenib in the treatment of thyroid cancer

http://www.wikidata.org/entity/Q26752891

about

Differentiated Thyroid Cancer-Treatment: State of the Art.Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.Tumor-Associated Macrophages as Target for Antitumor Therapy.Decreased WWOX expression promotes angiogenesis in osteosarcoma.Thrombosis in Thyroid Cancer.Prolonged duration of response in lenvatinib responders with thyroid cancer.Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.

P2860

Q33839037-E853695A-DB2A-4190-9037-B0D70343AF26 Q37153297-B501F304-9DC8-4B69-A38A-591836507DF1 Q37713334-F1DB0352-2D44-4436-93D7-0842378A82A2 Q39146689-D7D85062-DD3E-4AAC-A93C-F16CBCA0AFEC Q39403895-BD80277D-6F44-4640-B5E0-45FCAA59C6B0 Q42365252-856C15C1-0B1F-47C4-B344-6432D3C49695 Q52562627-DD4E1664-F57E-4C07-A112-94D5D7260E0D Q55413273-30F12BA7-FBCF-4403-9AD8-9B53CF281893 Q55514052-676C74E0-F433-4624-B65A-668E241F6E6E

P2860

Selective use of sorafenib in the treatment of thyroid cancer

http://www.wikidata.org/entity/Q26752891

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Selective use of sorafenib in the treatment of thyroid cancer

@ast

Selective use of sorafenib in the treatment of thyroid cancer

@en

Selective use of sorafenib in the treatment of thyroid cancer

@nl

type

label

Selective use of sorafenib in the treatment of thyroid cancer

@ast

Selective use of sorafenib in the treatment of thyroid cancer

@en

Selective use of sorafenib in the treatment of thyroid cancer

@nl

prefLabel

Selective use of sorafenib in the treatment of thyroid cancer

@ast

Selective use of sorafenib in the treatment of thyroid cancer

@en

Selective use of sorafenib in the treatment of thyroid cancer

@nl

P1433

Q26752891-DB07223A-8325-4EF4-B596-1F4703E07398

P1476

Q26752891-39068F40-5DB6-4FC9-8B84-7C76EA22C4BF

P2093

Q26752891-19845C5A-006E-43BA-A412-DB1E5CCD6284

Q26752891-EAA579DE-F21B-40A0-BDFA-FDB79FEA6598

P275

Q26752891-1CBADAA5-EF01-46C9-815B-25A738C4B4DD

P2860

Q26752891-048A7F9E-36B6-48A2-B84B-46303B92ED1D

Q26752891-0FE1E2D2-9124-4347-8472-511E1D3C7D0D

Q26752891-15787213-EBFA-4698-AA59-7E49F070F4C1

Q26752891-15A4E1A9-22E8-463E-8489-FEA04CE930A0

Q26752891-1A44736B-B795-4705-BB0F-8DF5A103004A

Q26752891-1A810BE5-A8CA-4340-A387-E2EE63E1011B

Q26752891-1E73625A-AB4A-4F8F-A2EE-BD1F800F4F1A

Q26752891-1EE78EDC-7D37-4B08-A79D-F7A883E77229

Q26752891-2213D231-F0F2-4076-8E91-8A5738CED0EF

Q26752891-2AAE7631-C981-4599-A77C-5891A68A443D

P304

Q26752891-D6CB3D17-5C74-44E2-B96D-618D0C383AB1

P31

Q26752891-27C3D483-3731-4D44-AFA6-714F9C751027

Q26752891-753B411D-BF81-443F-9624-3AF592801733

P356

Q26752891-25F21B59-5C7B-4E07-98B0-365D215DD90E

P407

Q26752891-1F5641E3-F573-4EC6-8F67-3EA015725207

P478

Q26752891-2294BCC9-FA31-4467-8FEF-9C53B7D0B5CE

P5008

Q26752891-5BD1EF62-EDF1-4E8E-B2D7-4D15855BAA55

P577

Q26752891-C79F535D-F573-4C7B-9C75-58ED7425ADEB

P698

Q26752891-BF3852AF-7950-496A-9024-952F0B9CDE4B

P921

Q26752891-01BA676C-0DE6-4D52-8A6C-37372799D4F2

Q26752891-0D52BC02-C11C-4F86-8FF2-4317F8EB06C1

Q26752891-0DD5149A-87B6-4902-AA66-D5DE13279B09

Q26752891-6B1722C1-54ED-4C2B-B18F-8BAAF8F33004

Q26752891-D2FC77F8-938C-4DD8-97F2-A2B6D1441D12

P932

Q26752891-87DB99E3-0757-4778-8ACC-B46B85B5DD96

P356

P1433

Drug Design, Development and Therapy

P1476

Selective use of sorafenib in the treatment of thyroid cancer

@en

P2093

Fabián Pitoia

http://www.w3.org/2001/XMLSchema#string

Fernando Jerkovich

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Global cancer statistics

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

RAS mutations in thyroid cancer

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

P304

1119-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S82972

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27042004

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

P932

4795584

http://www.w3.org/2001/XMLSchema#string